At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
AG-013736 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study To Evaluate The Pharmacokinetics Of AG-013736 In Subjects With Impaired Hepatic Function
In Brief
A Phase 1 clinical trial evaluating AG-013736 for Hepatic Insufficiency. Completed, enrolled 24 participants across 2 sites.
Detailed Summary
This study will evaluate the effects of mild and moderate impairment of hepatic function on the single-dose pharmacokinetics, safety and tolerability of AG-013736.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Insufficiency
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
First PostedJun 2008
Primary CompletionOct 2008
TodayJul 2026
First PostedJun 6, 2008
Enrollment StartMay 1, 2008
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 18.1 years ago
Interventions
AG-013736drug
Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
AG-013736drug
Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
AG-013736drug
Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.